Physicochemical Properties
| Molecular Formula | C42H62F3N11O11 |
| Molecular Weight | 954.00 |
| Related CAS # | ATWLPPR Peptide;272121-15-0 |
| Appearance | White to off-white solid powder |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | Neuropilin-1[2] |
| ln Vitro | ATWLPPR Peptide TFA is a neuropilin-1 inhibitor that selectively blocks VEGF165 binding to NRP-1, with an 82% inhibition at 100 μM[1]. |
| ln Vivo | ATWLPPR (400 μg/kg, sc) protects vascular integrity, lowers oxidative stress, and may lessen diabetes's early-onset retinal damage[2]. GFAP, VEGF, and ICAM-1 are three proteins linked to inflammation that ATWLPPR inhibits from rising in the retina[2]. |
| References |
[1]. Structure-function analysis of the antiangiogenic ATWLPPR peptide inhibiting VEGF(165) binding to neuropilin-1 and molecular dynamics simulations of the ATWLPPR/neuropilin-1 complex. Peptides. 2007 Dec;28(12):2397-402. [2]. The Neuropilin-1 Inhibitor, ATWLPPR Peptide, Prevents Experimental Diabetes-Induced Retinal Injury by Preserving Vascular Integrity and Decreasing Oxidative Stress. PLoS One. 2015 Nov 10;10(11):e0142571. |
Solubility Data
| Solubility (In Vitro) | H2O :~100 mg/mL (~104.82 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (104.82 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.0482 mL | 5.2411 mL | 10.4822 mL | |
| 5 mM | 0.2096 mL | 1.0482 mL | 2.0964 mL | |
| 10 mM | 0.1048 mL | 0.5241 mL | 1.0482 mL |